IL-21

IL-21 詳細

英語名Interleukin-21市販薬剤の数0
治験薬の数4ターゲットの別称Za11,IL-21,CVID11,Interleukin-21 Isoform,Interleukin 21
研究&開発段階Phase 2 Clinical
英語名Interleukin-21
ターゲットの別称Za11,IL-21,CVID11,Interleukin-21 Isoform,Interleukin 21
市販薬剤の数0
治験薬の数4
研究&開発段階Phase 2 Clinical

IL-21 製品リスト

  • 属性

    Protein (11)Kits (1)

  • 製品ライブラリ

    オンライン (12)

  • Human (9)Cynomolgus (2)Mouse (1)

  • タグ

    Fc Tag & Avi Tag (1)Fc Tag (2)Tag Free (6)His Tag (2)- (1)

  • マーカー

    Biotin-labeled (1)Unconjugated (10)- (1)

IL-21バックグランド

Interleukin-21 (IL-21) is a secreted protein which belongs to the IL-15 / IL-21 family. Interleukin-21 / IL-21 belongs to a family of cytokines that bind to a composite receptor consisting of a private receptor (IL21R) and the common cytokine receptor gamma chain (gamma(C)). Interleukin-21 / IL-21 impacts a number of cell types, including CD8+ memory T cells, NK cells and subsets of CD4 memory T cells. The IL-21R is widely distributed on lympho-haematopoietic cells. IL-21 is a pleiotropic cytokine produced by CD4+ T cells in response to antigenic stimulation. Its action generally enhances antigen-specific responses of immune cells. IL-21 promotes the anti-tumor activity of CD8+ T-cells and NK cells. IL-21 exerts its effect through binding to a specific type I cytokine receptor, IL-21R, which also contains the γ chain (γc) found in other cytokine receptors including IL-2, IL-4, IL-7, IL-9 and IL-15. The IL-21/IL-21R interaction triggers a cascade of events which includes activation of the tyrosine kinases JAK1 and JAK3, followed by activation of the transcription factors STAT1 and STAT3.

IL-21分子の別称

IL21,Za11,Interleukin-21

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
CVD-1301.V01hV-01; CVD-1301.V01; V 01Phase 2 ClinicalHangzhou Converd Co LtdPancreatic Neoplasms; Sarcoma 180; Solid tumours; Uterine Cervical Neoplasms
詳細
IL-21 mab (Lilly)Phase 1 ClinicalEli Lilly And CompanyImmune System Diseases
詳細
triple anti-CD19 CAR T-cell therapy/PD-1 checkpoint inhibitor/IL-21 receptor agonist (CD (Suzhou) Biopharma/Chinese People's Liberation Army General Hospital/Chinese academy of sciences)Phase 1 ClinicalChinese Academy Of SciencesHematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma
詳細
CD-001CD-001Phase 1 ClinicalCD (Suzhou) Biopharma Co LtdHead and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Solid tumours
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8